


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-22. (Canceled)

23. (Currently Amended) A compound of formula I, stereoisomeric and tautomeric forms and mixtures thereof ~~in all ratios~~, and physiologically tolerated salts, ~~hydrates~~ and esters thereof:



wherein:

R₁ is chosen from hydrogen, ~~(C₁-C₂₀)-alkyl, (C₁-C₂₀)-alkenyl, (C₁-C₂₀)-alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, alkylaryl, and arylalkyl~~, wherein the ~~organic radicals may be substituted by at least one substituent~~,

R₂ is chosen from, independently of R₁, hydrogen, (C₁-C₂₀)-alkyl, ~~(C₁-C₂₀)-alkenyl, (C₁-C₂₀)-alkynyl, cycloalkyl, cycloalkenyl, and cycloalkylalkyl~~, and ~~aryl, alkylaryl, and arylalkyl~~, wherein the ~~organic radicals may be substituted by at least one substituent, or~~

~~R₄ and R₂ may, together with the nitrogen atom bearing them, form a 3-8 membered ring which may optionally contain 0, 1 or 2 further heteroatoms chosen from N, O, and S, and which is optionally substituted by at least one radical,~~

R₄ is chosen from phenyl, ~~(C₄-C₂₀)-alkyl, (C₄-C₂₀)-alkenyl, (C₄-C₂₀)-alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, (C₄-C₂₀)-alkylaryl, (C₁-C₂₀)-alkylphenyl, and (C₂-C₂₀)-alkyl, arylalkyl, CO-O-alkyl, CO-O-aryl, CO-alkyl, and CO-aryl, wherein the organic radicals may be which is optionally substituted by at least one substituent with -OH, alkyloxy or halogen,~~

R₁₁ is chosen from ~~hydrogen, (C₄-C₂₀)-alkyl, (C₁-C₅)-alkyl, aryl, CO-alkyl, and CO-aryl, wherein the organic radicals may be which is optionally substituted by at least one substituent,~~


R₁₂ and R₁₃ are independently chosen from ~~hydrogen, (C₄-C₄₀)-alkyl, and (C₁-C₅)-alkyl, aryl, O-(C₄-C₄₀)-alkyl, O-phenyl, O-CO-(C₄-C₄₀)-alkyl, O-CO-aryl, NR₈R₉, phenyl, CO-(C₄-C₄₀)-alkyl, CF₃, CN, CONR₈R₉, COOH, CO-O-(C₄-C₄₀)-alkyl, CO-O-aryl, F and Cl, which is optionally substituted,~~

~~R₈ is chosen from hydrogen and (C₄-C₂₀)-alkyl,~~

~~R₉ is chosen from hydrogen, (C₄-C₂₀)-alkyl, and aryl, and~~

~~n is 0, 1 or 2,~~

~~with the proviso that compounds of the formula (Ia)~~



~~wherein in formula (Ia) R₁, R₂, R₃ and R₄ are independently chosen from H and OH,~~

~~R₅ is chosen from H, CH₃, CH₂OH, CHO, a lower (C₄-C₉)-alkyl radical, which can be a straight or a branched chain, (CH(OH))_n-Y and (CH(OH))_n-(CH₂)_m-W, wherein Y is hydrogen or a lower alkyl (C₄-C₉)-radical, W is hydrogen or a hydroxyl group, and n and m are independently from each other 1-20.~~

24. (Currently Amended) The compound of claim 23, wherein:

R₁ is hydrogen,

R₂ is chosen from hydrogen, (C₁-C₂₀)-alkyl and cycloalkylalkyl,

R₄ is chosen from phenyl, (C₁-C₂₀)-alkylphenyl and (C₁₂-C₂₀)-alkyl which is optionally substituted with -OH, alkyloxy or halogen, and

~~R₁₁, R₁₂ and R₁₃ are independently of each other chosen from hydrogen and is methyl,~~
and

R₁₂ and R₁₃ are independently of each other chosen from hydrogen and methyl.

25-27. (Canceled)

28. (Currently Amended) The compound of claim ~~27~~ 23, wherein:

R₁ and R₂ are hydrogen,

R₄ is 1,2-dihydroxypropyl

R₁₁ is chosen from methyl and ethyl, and

R₁₂ and R₁₃ are independently of each other chosen from hydrogen and methyl.

29-30. (Canceled)

31. (Previously Presented) A pharmaceutical composition comprising a
pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of
a compound according to claim 23, or a pharmaceutically acceptable acid addition salt
thereof.

32-42. (Canceled)